ArticleJournal of the American Heart Association2026
Blood Biomarkers and the Risk of Coronary Disease in Atrial Fibrillation.
Article in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAtrial fibrillation (AF) is the most common arrhythmia. Although it was recently identified as a risk factor for coronary heart disease (CHD), the underlying pathophysiology is not well understood. Biomarkers could provide insights on underlying mechanisms and identify potential predictors of CHD among people with AF.
methodsThe REGARDS (Reasons for Geographic and Racial Differences in Stroke) cohort study enrolled 30 239 White and Black adults aged 45 and older in 2003 to 2007. Among those with baseline AF and no history of stroke or CHD, 13 cardiovascular risk biomarkers were measured at baseline. We calculated hazard ratios (HR) for incident CHD by biomarkers using Cox proportional hazards model adjusting for risk factors and use of statins, aspirin, and anticoagulants.
resultsAmong 1818 participants with prevalent AF mean age was 69 years (SD 10 years). There were 201 (11%) cases of incident CHD over 9 years. Several biomarkers were associated with incident CHD: NT-proBNP (N-terminal pro-B-type natriuretic peptide), GDF-15 (growth differentiation factor 15), C-reactive protein, interleukin-6, D-dimer, cholesterol, lipoprotein(a), triglycerides, low-density lipoprotein, and gamma-glutamyl transferase, with HRs 1.17 to 1.69 per SD increment. There were no associations for Factor VIII, galectin 3, and high-density lipoprotein. The largest associations were for NT-proBNP and GDF-15 with respective HRs per SD 1.69 (95% CI, 1.42-2.01) and 1.45 (95% CI, 1.21-1.74). Comparing the top versus bottom tertile, the largest associations were NT-proBNP (HR 3.14 [95% CI 2.03-4.84]), interleukin-6 (HR, 2.69 [95% CI, 1.78-4.06]), and GDF-15 (HR, 2.20 [95% CI, 1.38-3.51]).
conclusionsMultiple biomarkers were associated with incident CHD in AF with the largest associations being myocardial strain and inflammation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.